Evidence map›Paper›PMID 26487830›Full record

ReviewNeural regeneration research2015

Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease.

Madhuri Venigalla, Erika Gyengesi, Gerald Münch

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neural regeneration research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Pharmacokinetic Analysis of the Bioavailability of AQUATURMPharmaceuticals (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Novel Anti-Acetylcholinesterase Effect ofLife (Basel, Switzerland) · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Madhuri VenigallaDepartment of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, NSW, Australia.
Erika GyengesiDepartment of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, NSW, Australia ; Molecular Medicine Research Group, University of Western Sydney, Penrith, NSW, Australia.
Gerald MünchDepartment of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, NSW, Australia ; National Institute of Complementary Medicine, University of Western Sydney, Penrith, NSW, Australia ; Molecular Medicine Research Group, University of Western Sydney, Penrith, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Current treatments for Alzheimer's disease primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for Alzheimer's disease patients. This review will provide an overview of the proven antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of curcumin and apigenin and discuss the potential of these compounds for Alzheimer's disease prevention and treatment. We suggest that these compounds might delay the onset of Alzheimer's disease or slow down its progression, and they should enter clinical trials as soon as possible.

Indexed as

Alzheimer's diseaseanti-inflammatory drugsneuroinflammationplant secondary metabolitesreactive oxygen species

Identifiers

PMID26487830
PMCPMC4590215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.